NIKA PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.599 USD | -19.91% |
|
+318.88% | -.--% |
| 03-20 | Nika Pharmaceuticals, Inc. (OTCPK : NKPH) acquired Nika BioTechnology, Inc. | CI |
| 2023 | Nika Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt | CI |
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Net sales | - | - | - | - |
| EBITDA | - | - | - | - |
| EBIT 1 | -0.008907 | -0.0147 | -3.184 | -0.0648 |
| Operating Margin | - | - | - | - |
| Earnings before Tax (EBT) 1 | -0.008907 | -0.0147 | -3.184 | -0.0648 |
| Net income 1 | -0.008907 | -0.0147 | -3.184 | -0.0648 |
| Net margin | - | - | - | - |
| EPS 2 | -0.000022 | -0.000037 | -0.004397 | -0.000074 |
| Free Cash Flow | - | - | 1.168 | -0.0405 |
| FCF margin | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 3/24/21 | 3/3/22 | 4/10/23 | 4/1/24 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Net Debt 1 | 0.01 | 0.02 | - | 0.08 |
| Net Cash position 1 | - | - | 0 | - |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow | - | - | 1.17 | -0.04 |
| ROE (net income / shareholders' equity) | - | 90.5% | 15,555% | 130% |
| ROA (Net income/ Total Assets) | - | -915% | -315,344% | -396% |
| Assets 1 | - | 0.001608 | 0.00101 | 0.0164 |
| Book Value Per Share 2 | -0 | -0 | -0 | -0 |
| Cash Flow per Share 2 | 0 | 0 | - | 0 |
| Capex | - | - | - | - |
| Capex / Sales | - | - | - | - |
| Announcement Date | 3/24/21 | 3/3/22 | 4/10/23 | 4/1/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
- Stock Market
- Equities
- NIKA Stock
- Financials Nika Pharmaceuticals, Inc.
